Neuropace Inc
NASDAQ:NPCE

Watchlist Manager
Neuropace Inc Logo
Neuropace Inc
NASDAQ:NPCE
Watchlist
Price: 11.98 USD 3.1% Market Closed
Market Cap: 390.1m USD

Neuropace Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Neuropace Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Neuropace Inc
NASDAQ:NPCE
Revenue
$79.9m
CAGR 3-Years
21%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Revenue
$20.6B
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
9%
Boston Scientific Corp
NYSE:BSX
Revenue
$17.6B
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
9%
Stryker Corp
NYSE:SYK
Revenue
$22.6B
CAGR 3-Years
10%
CAGR 5-Years
9%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Revenue
$42.3B
CAGR 3-Years
-2%
CAGR 5-Years
6%
CAGR 10-Years
8%
Intuitive Surgical Inc
NASDAQ:ISRG
Revenue
$8.7B
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
15%

Neuropace Inc
Glance View

Market Cap
361.1m USD
Industry
Health Care

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.

NPCE Intrinsic Value
10.06 USD
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Neuropace Inc's Revenue?
Revenue
79.9m USD

Based on the financial report for Dec 31, 2024, Neuropace Inc's Revenue amounts to 79.9m USD.

What is Neuropace Inc's Revenue growth rate?
Revenue CAGR 5Y
17%

Over the last year, the Revenue growth was 22%. The average annual Revenue growth rates for Neuropace Inc have been 21% over the past three years , 17% over the past five years .

Back to Top